For research use only. Not for therapeutic Use.
Nitroxyl (HNO) is a reactive nitrogen species that improves myocardial function by direct positive cAMP-independent lusitropic and inotropic effects and by combined venous and arterial dilation. CXL-1020 is an HNO donor which nonenzymatically decomposes to produce pure HNO. HNO donors are potentially useful for the treatment of heart failure. KEYWORDS: CXL-1020 | supplier | HNO donor | 2-MSPA | 2MSPA | CXL1020 | CXL 1020 | CAS [950834-06-7] | Cysteine residues | HNO donor
| Catalog Number | I025314 |
| CAS Number | 950834-06-7 |
| Molecular Formula | C7H9NO5S2 |
| Purity | ≥95% |
| IUPAC Name | N-hydroxy-2-methylsulfonylbenzenesulfonamide |
| InChI | InChI=1S/C7H9NO5S2/c1-14(10,11)6-4-2-3-5-7(6)15(12,13)8-9/h2-5,8-9H,1H3 |
| SMILES | CS(=O)(=O)C1=CC=CC=C1S(=O)(=O)NO |
| Reference | A Arcaro et al. Nitroxyl (HNO) for treatment of acute heart failure. Curr Heart Fail Rep. 2014 Sep;11(3):227-35. HN Sabbah et al. Nitroxyl (HNO): A novel approach for the acute treatment of heart failure. Circ Heart Fail. 2013 Nov;6(6):1250-8. Diering, S. et al. Receptor-independent modulation of cAMP-dependent protein kinase and protein phosphatase signaling in cardiac myocytes by oxidizing agents. J. Biol. Chem. 2020, in press.* Both NCA and CXL-1020 were synthesized by Axon Medchem. |
